ARVN Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 4.36%, SMA50 7.61%, SMA200 40.5%). The stock’s 14-day RSI is 58.04 (neutral), while the ATR of 0.79 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.32% below its high and over 126.78% above its low. Average 10-day trading volume of 1.12 million shares is slightly above the 3-month average of 794.81 thousand, indicating heightened recent market interest.

Arvinas, Inc. has 64.22 million shares outstanding. The public float is 55.47 million shares, elevated short interest at 6.42% of float. This equals 4.05 million shares. The short ratio is 5.22 days. Institutional investors hold 104.72% of the float. Insiders own 7.88%. SHANNON TIMOTHY M holds 1.65 million shares, Houston John G has 1.12 million shares and Ratcliffe Liam has 185.69 thousand shares. Over the past six months, insider transactions show net selling. They sold 40.27 thousand shares across 10 transactions.

Arvinas, Inc. generated EPS of -$1.22 over the past year. Five-year average earnings growth is 17.7%. Wall Street analysts project EPS growth of -27.17% annually over the next five years. The latest quarter delivered EPS of -$0.48. The next quarter is forecast at -$0.93. Next year's EPS is expected at -$37.32. Analyst sentiment is bullish. Analyst rating data shows there are 9 Strong Buy ratings, 10 Buy ratings, 2 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $81.00 to $6.00. The high target offers 640.4% upside. The low target suggests -45.16% downside. The mean target is $18.39. This offers 68.1% upside. Arvinas, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 05, 2025, missed forecasts by -35.8%. The prior quarter beat by -3.45%. Over the last six quarters, Apple has recorded several small beats. These include -31.94% in July 30, 2024.

Arvinas, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$17.57. This means the shares are trading below this model’s fair value.

Arvinas, Inc. (NASDAQ:ARVN) closed at $10.94 USD, losing -$0.23 (-2.06%) from the previous close of $11.17. The stock is currently mid-range between its 52-week high and low $5.90 and $14.51. With a market capitalization of about $702.61 million, Arvinas, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.94). Key stats such as the average daily volume over the past year has been around 815.66 thousand shares, trading with heavier-than-usual volume. Headquartered in New Haven, CT, Arvinas, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Randy Teel, the company employs approximately 430 people and listed since September 27, 2018. Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Arvinas, Inc. trades at a P/E ratio of -8.79, slightly below the S&P 500 average, with a price-to-sales ratio of 2.68 and a price-to-book ratio of 1.64 suggesting the stock is closer to book value. The P/FCF stands at -2.55, also below market averages.

Arvinas, Inc. (NASDAQ:ARVN) shares are flat 1.43% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Arvinas, Inc. trading at a premium to the broader market with a P/E of -8.79. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $53.98, suggesting 393.42% upside. Our AI forecast model points to short-term weakness (-0.82% over two weeks), a medium-term rise (129.52% over three months), and a longer-term gain (65.45% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Arvinas, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.82%, with price expected at $10.85 by April 03, 2026, within a range of $9.97 to $11.76 3-Month Outlook: Projected rise of 129.52%, reaching $25.11 by June 18, 2026, with a range of $24.26 to $26.08. 1-Year Outlook: Projected gain of 65.45%, with price at $18.10 by March 19, 2027, within a range of $0.00 to $26.11.